SZTURZ, Petr, Zdeněk ADAM, Jana CHOVANCOVÁ, Olga STEHLÍKOVÁ, Martin KLABUSAY, Z. ŘEHÁK, R. KOUKALOVÁ, Lenka ZAHRADOVÁ, Marta KREJČÍ, Luděk POUR, Roman HÁJEK and Jiří MAYER. Lenalidomide: a new treatment option for Castleman disease. Leukemia & Lymphoma. LONDON: INFORMA HEALTHCARE, 2012, vol. 53, No 10, p. 2089-2091. ISSN 1042-8194. doi:10.3109/10428194.2011.621564.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Lenalidomide: a new treatment option for Castleman disease
Authors SZTURZ, Petr (203 Czech Republic, belonging to the institution), Zdeněk ADAM (203 Czech Republic, guarantor, belonging to the institution), Jana CHOVANCOVÁ (203 Czech Republic, belonging to the institution), Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution), Martin KLABUSAY (203 Czech Republic, belonging to the institution), Z. ŘEHÁK (203 Czech Republic), R. KOUKALOVÁ (203 Czech Republic), Lenka ZAHRADOVÁ (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Leukemia & Lymphoma, LONDON, INFORMA HEALTHCARE, 2012, 1042-8194.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.301
RIV identification code RIV/00216224:14110/12:00060973
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3109/10428194.2011.621564
UT WoS 000308213400024
Keywords in English Lenalidomide; Castleman disease
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 28. 11. 2012 14:22.
Abstract
A male born in 1961, aged 46, was referred to our department for evaluation of splenomegaly and generalized lymphadenopathy aff ecting the cervical, axillary, mediastinal, retroperitoneal and inguinal regions. Laboratory data revealed an increased erythrocyte sedimentation rate (16 mm/h and 30 mm/2 h) and C-reactive protein level (35.4 mg/L). Total protein and full blood counts as well as renal and hepatic profi les were within normal ranges, and microbiological screening revealed no infectious etiology. Other fi ndings, including radiological examinations and bone marrow biopsy, showed no further pathologies. Th e patient ’ s other medical history was signifi cant for arterial hypertension, chronic infl ammatory demyelinating polyneuropathy and mild right hemi-paresis with expressive language disorder. Based on lymph node biopsies from retroperitoneal and both inguinal regions, the patient was diagnosed with the plasma-cell variant of CD. Th e presence of a large pelvic mass compressing adjacent structures indicated the patient for therapy initiation. During fi rst-line treatment (R-CHOP: rituximab 375 mg/m 2 , cyclophosphamide 750 mg/m 2 , doxorubicin 50 mg/m 2 and vincristine 2 mg intravenously on day 1; prednisone 100 mg perorally on days 1 – 5 in a 21-day cycle, three cycles in total, 12/2008 – 2/2009), clinical progression of the disease was evident (gastrointestinal symptoms, swollen hands and feet with signs of vasculitis), and there was no radiological response on a restaging computed tomography (CT) examination after 3 months.
Links
LC06027, research and development projectName: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, Basic Research Center
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, Research Intents
NS9671, research and development projectName: Stanovení hladiny cytokinů a kostimulačních molekul v plasmě, kostní dřeni, leukocytech a nádorových buňkách nemocných s hematologickými malignitami a jejich vztah k aktivitě nemoci, transplantaci krvetvorby, rozvoji komplikací (GvHD) a riziku relapsu.
Investor: Ministry of Health of the CR, Departmental Programme of Research and Development - MH II from 2008 to 2011
NT11154, research and development projectName: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu
Investor: Ministry of Health of the CR
PrintDisplayed: 28. 10. 2021 01:56